Sign up to save your podcasts
Or
Share Evolving Pharmacologic Intervention for Methamphetamine Use Disorder: A Focus on ADAPT-2
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Evolving Pharmacologic Intervention for Methamphetamine Use Disorder: A Focus on ADAPT-2
CME credits: 0.25
Valid until: 15-04-2024
Claim your CME credit at https://reachmd.com/programs/cme/evolving-pharmacologic-intervention-for-methamphetamine-use-disorder-a-focus-on-adapt-2/12907/
Join Drs. Madhukar Trivedi and Steven Shoptaw as they discuss the evolving landscape of pharmacologic intervention for methamphetamine use disorder. Their focus will be on evidence from the ADAPT-2 clinical trial supporting the combination of extended release naltrexone and high dose bupropion to reduce methamphetamine use for patients with moderate to severe methamphetamine addiction. These important data from ADAPT-2 offer a significant therapeutic advance for methamphetamine use disorder that can be taken into the clinic.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 15-04-2024
Claim your CME credit at https://reachmd.com/programs/cme/evolving-pharmacologic-intervention-for-methamphetamine-use-disorder-a-focus-on-adapt-2/12907/
Join Drs. Madhukar Trivedi and Steven Shoptaw as they discuss the evolving landscape of pharmacologic intervention for methamphetamine use disorder. Their focus will be on evidence from the ADAPT-2 clinical trial supporting the combination of extended release naltrexone and high dose bupropion to reduce methamphetamine use for patients with moderate to severe methamphetamine addiction. These important data from ADAPT-2 offer a significant therapeutic advance for methamphetamine use disorder that can be taken into the clinic.
=